AU769095B2 - Rapid and sensitive method for detecting (Histoplasma capsulatum) - Google Patents

Description

WO 99/54508 PCT/US99/08731 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA

CAPSULATUM

FIELD OF THE INVENTION This invention relates to detecting a pathogenic fungus, Histoplasma capsulatum, using oligonucleotide probes specific for H. capsulatum to amplify H.

capsulatum DNA by means of the polymerase chain reaction. Test samples may originate from the environment, where H. capsulatum spores are found, or from clinical samples obtained from patients.

BACKGROUND OF THE INVENTION Histoplasma capsulatum is a dimorphic fungus that is pathogenic in humans.

In one form, the fungus has the mycelia characteristic of molds, and produces spores as an aspect of its reproduction. This form is commonly found in the ambient environment, and is highly prevalent in soils containing guano from bats or birds. In general it proliferates in soils rich in nutrients such as those containing rotting organic residues. Its morphology includes multicellular filaments containing cylindrical structures the hyphae or conidia). This form may further contain macroconidia and microconidia which may grow in soil or on media designed for fungal growth at In its second form, H. capsulatum adopts a single celled state characteristic of yeast, and reproduces by budding. This form is prevalent on suitable nutrient media in the laboratory, and is the form generally found after it infects a human.

Infection may occur upon breathing dust containing fragments of H. capsulatum hyphae or conidia; as noted above, such fragments may be prevalent if dust is stirred up from soil containing the droppings from birds or bats or soil that is otherwise rich in organic nutrients, especially nitrogenous nutrients.

The infection produces a systemic fungal disease, histoplasmosis, which can initially result in a variety of symptoms often dependent on the type of infection, the general health of the host, and the exposure level. In acute self-limiting SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 infections, especially those occurring in healthy individuals, the symptoms may be very mild, such as those of a flu-like respiratory illness, with symptoms such as general malaise, fever, chest pain, a dry cough, headache, loss of appetite, shortness of breath, joint and muscle pains and chills. The severity of the symptoms may depend on how many spores have been inhaled, and the general health of the subject.

The symptoms of respiratory infection are often suppressed by the immune response. This response includes endocytosis by pulmonary macrophages.

H.

capsulatum may then proliferate within macrophages and be transported systemically as a result. As a result, such suppression appears to result in long term latency rather than in elimination of the organism. H. capsulatum infection can also result in calcified deposits within the lungs, produced when growth of the yeast is inhibited by host immune responses. Both the infected macrophages and the calcified deposits serve as a reservoir of latent infection. As a consequence, if the individual subsequently becomes immune compromised or immune deficient, histoplasmosis can reappear. Thus individuals such as those receiving immunesuppressing therapy, the very young or the elderly, those suffering from cancer, or expressing the symptoms of acquired immune deficiency syndrome are susceptible to recrudescence of histoplasmosis as a chronic and/or a disseminated infection, and may include ocular infection. Resurgence of such latent histoplasmosis produces potentially lethal symptoms.

Assay for H. capsulatum infection or its presence in a sample is carried out by methods such as culturing, immunoassay for surface antigens, and a bioassay.

Currently, histoplasmosis may be diagnosed by culture, or by the demonstration of a rise in complement-fixing antibody titers in serum. A definitive diagnosis of an H. capsulatum infection requires the isolation and propagation of the fungus, which is time-consuming and lacks sensitivity. It is also dangerous for laboratory personnel, who must take extreme caution to prevent inhalation of tile pathogenic fungus, so as not to become ill with a pulmonary infection. Further, only small quantities of antigens of H. capsulatum for use as biological reagents may be prepared in this manner.

Conventional laboratory identification methods used to isolate and identify H. capsulatum include the culture of a clinical specimen at room temperature on -2- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 specialized fungal media. This procedure isolates the slower growing H.

capsulatum colonies from possible contaminants, such as bacteria, and from faster growing saprobic fungi. This method, however, has several disadvantages.

Because the growth of H. capsulatum to a visible colony normally takes from about two to four weeks, and sometimes as long as 12 weeks, this identification procedure is very slow. (See, for example, Rippon, Histoplasmosis. In Medical Mycology, The Pathogenic Fungi and the Pathogenic Actinomvestes, 3rd Ed., Saunders, Ch. 15 (1988); Koneman at al., Laboratory Identification of Molds, in Practical Laboratory Mycology, (3rd ed. Williams Wilkins (1985)); and McGinnis, Histoplasma capsulatum, in Laboratory Handbook of Medical Mycology.

Academic Press (1986).) Further, additional growth is required before the characteristic colony morphology and microscopic sporulation pattern with tuberculate macroconidia may be observed. In addition, approximately 10% of cultures produce only smooth-walled macroconidia, and some cultures fail to sporulate. Moreover, many species of fungi other than H. capsulatum, such as Blastomyces dermatitides, Chryacsporium sp., and Sepedonium sp., produce similar colony and sporulation characteristics. Thus, additional testing is usually necessary to definitively identify the organism.

One method of converting the mycelial colony of H. capsulatum to the yeast phase is performed by subculturing the organism onto highly enriched cysteinecontaining media, and incubating it at 35-37 0 C. However, conversion to the yeast phase is often difficult, and may require several additional subcultures at three-day intervals.

Histoplasmin, an unpurified culture supernatant obtained from the mycelial phase of H. capsulatum contains H. capsulatum M antigens. Histoplasmin is currently used to probe both humoral and cell-mediated responses in patients with histoplasmosis. It is used for the serologic diagnosis of histoplasmosis, and as a skin test antigen to demonstrate delayed hypersensitivity to infection in skin tests for histoplasmosis. The purification of histoplasmin is described by Bradley et al., Infect. Immun. 9:870-880 (.1974). The preparation of H and M antigens of H.

capsulatum free of heterologous antigens is described by Green et al., Curr.

Microbiol. 12:209-216 (1985). (See also, Pine, Contrib. Microbiol. Immunol.

3:138-168 (1977).) The preparation of antisera to the M antigen is described by -3- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 Green et al., Infect. Immun. 14:826-831 (1976). General information concerning the serodiagnosis of fungal diseases is present in Kaufman et al., Serodiagnosis of Fungal Diseases, in Manual of Clinical Laboratory Immunology (3rd ed., American Society for Microbiology, Washington, D.C.(1988)).

Serologic evidence is a principal diagnostic indicator of histoplasmosis.

Several serologic tests, such as the immunodiffusion test, detect precipitants against the species-specific H and M antigens found in histoplasmin. (See, for example, Kaufman, Clin. Infect. Dis. 14:23-29 (1992), and Wheat, Eur. J. Clin.

Microbiol. Infect. Dis. 8:480 (1989).) Although the M antigen of H. capsulatum is useful in immunoassays for the diagnosis of histoplasmosis, purification of the M antigen from a batch culture is a laborious and low-yield process. The use of a recombinantly-produced M antigen of H. capsulatum in such immunoassays would significantly diminish the labor necessary to obtain M antigens which are pure enough to be useful in the immunoassays, and would result in high yields of the M antigen.

Assay for H. capsulatum infection historically has been via immunoassay for surface antigens. Additionally, a widely practiced assay is the mouse inoculum/agar plate culture method. This method, which involves indirect detection, takes as long as 6-8 weeks and is expensive. The method entails extracting a soil sample suspected of harboring H. capsulatum and injecting the extract intraperitoneally into mice. After six weeks the mice are sacrificed, and extracts of the livers and spleens are inoculated onto Sabouraud's dextrose agar.

These are incubated and observed weekly for fungal growth. Any fungi resulting are then subcultured for a more definitive identification. (Ajello, L. and Weeks, in Occupational Mycoses, A Text, edited by A.F. DiSalvo, Leas Febiger, Philadelphia, pp.229 238, 1983; Ajello, L. and Runyon, J. Bacteriol. 66:34- 1953). More recently molecular biological assay techniques have been developed, such as restriction fragment length polymorphism

(RFLP).

U.S. Patent 5,580,971 to Mitsuhashi discloses methods for detecting a particular fungus in a biological sample based on polynucleotide capture probes.

In one method, the probe is complementary to a sequence in the ribosomal RNA of a particular fungus, and binding of the analyte nucleic acid is detected with a second probe whose sequence is common to a wide range of fungi. In another -4- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 method, two probes are used and nucleic acid is amplified using, preferably, a polymerase whose activity is not hindered at high temperature. Many species and genera of pathogenic fungi are detectable, but H. capsulatum is not included in the disclosed group of fungi.

WO 96 19588 discloses a nucleic acid hybridization probe derived from the saccharopine dehydrogenase of Candida albicans that is conserved in fungi. The probe, and an assay method employing the probe, may be used for detection of a variety of fungi from different genera. WO 96 21741 discloses oligonucleotide probes considered to be universal primers for 28S rRNA of fungi. An extensive range of species and genera of fungi is disclosed as being detectable by amplification methods using the probes, including H. capsulatum.

Padhye et al. Clin. Microbiol. 30, 3108-3111 (1992)) describe application of the Accuprobe T (Gen Probe, Inc., San Diego, CA) assay for H. capsulatum.

Accuprobe is a DNA-based probe in which hybridization between the probe and RNA from the organism is detected by a chemiluminescent assay. 103 of 105 H.

capsulatum samples were identified by the assay, with assay times of about 2 hrs.

Hall (Arch. Pathol. Lab. Med. 117, 578-583 (1993)) reviews applications of the AccuprobeM assay in general, and summarizes the organisms for which AccuprobesM were available. H. capsulatum is included among these. Hall does not provide the structure of the H. capsulatum probe.

Spitzer et al. (Infect. Immun. 57, 1409-1412 (1989)) disclose classification of ambient and clinical isolates of H. capsulatum based on analysis of mitochondrial DNA and ribosomal DNA. Keath et al. Clin. Microbiol. 30, 2104-2107 (1992)) present analyses of a large number of clinical and soil samples of H. capsulatum using restriction fragment length polymorphisms (RFLP). The nuclear gene probe yps-3 and a mitochondrial DNA probe were employed, and permitted classification into the known, as well as the identification of new, classes and subclasses of the fungus.

Kersulyte et al. Bact. 174, 7075-7079 (1992)) show that a polymerase chain reaction-based amplification based on random primers drawn from the fungal genome, and RFLP analysis resolves various isolates of H. capsulatum into a range of strains. They find that H. capsulatum is an extremely diverse species.

Woods et al. Clin. Microbiol. 31, 463-464 (1993)) teach that use of randomly SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 chosen primers for use in the polymerase chain reaction allows simple and rapid detection of variant isolates of H. capsulatum. They describe a rapid isolation method to obtain DNA from H. capsulatum in order to permit sensitive identification of H. capsulatum strains.

U.S. Patent 5,352,579 to Milliman discloses probes for the detection of Histoplasma capsulatum which distinguishes between H. capsulatum and its known closest phylogenetically related organisms. The invention is based on a hybridization probe capable of effecting this distinction. The probe is complementary to a variable region of rRNA or rDNA. A method of assaying for H. capsulatum using this probe is also provided. Mayer et al. (96th General Meeting, Amer. Soc. for Microbiol., New Orleans, LA, May 19-23, 1996) have devised a set of PCR probes (whose sequences were not disclosed) that are complementary to the gene for the H antigen of H. capsulatum var. capsulatum and var. duboisii that amplifies H. capsulatum DNA with specificity and sensitivity.

They also disclose the use of a nucleotide probe in a TaqMan assay, wherein the probe hybridizes to a region of H. capsulatum between the binding sites of two PCR probes. In the assay Taq polymerase liberates a luminescent probe from a quenching environment if the probe binds target DNA.

Presently, the method used to isolate and identify H. capsulatum is expensive and requires several weeks to complete. The expense is increased by the number of samples required. If not enough samples are collected, small but highly contaminated areas can be overlooked. See, "Histoplasmosis: Protecting Workers at Risk", Dept. of Health and Human Services Publication No. 97-146, Sept. 1997. Therefore, in the current status of the field, there remains a need for a specific, sensitive, and rapid assay for H. capsulatum, both in environmental samples and in clinical samples from patients suspected of harboring H. capsulatum infection. The present invention provides such methods and assays.

SUMMARY OF THE INVENTION The present invention provides oligonucleotides which are useful as primers to initiate the amplification of a segment of H. capsulatum DNA that is -6- SUBSTITUTE SHEET (R ULE 26) 7 specific to H. capsulatum using the polymerase chain reaction. The present invention also provides methods of detecting the presence of H. capsulatum in a sample using a nested, or two-stage, PCR assay.

Accordingly, in a first aspect of the present invention there is provided an oligonucleotide primer pair comprising sequences specific for the 5.8S rRNA gene of Histoplasma capsulatum, wherein both primers of said primer pair are specific for Histoplasma capsulatum 5.8S rRNA, and wherein both primers of said pair specifically amplify 5.8S rRNA gene sequence, or an oligonucleotide comprising a sequence complementary to one or the other of the primer pair specific for the H. capsulatum 5.8S rRNA gene.

According to a second aspect of the present invention there is provided an oligonucleotide comprising a sequence given by SEQ ID NO:3 or a sequence complementary to that given by SEQ ID NO:3, wherein the sequence of SEQ ID NO:3 defines the 3' end of the oligonucleotide or wherein the sequence complementary to SEQ ID NO:3 defines the 3' end of the oligonucleotide.

According to a third aspect of the present invention there is provided an oligonucleotide comprising a sequence given by SEQ ID NO:4 or a sequence complementary to that given by SEQ ID NO:4, wherein the sequence of SEQ ID NO:4 defines the 3' end of the oligonucleotide or wherein the sequence complementary to SEQ 20 ID NO:4 defines the 3' end of the oligonucleotide.

According to a fourth aspect of the present invention there is provided a method of detecting H. capsulatum in a sample, said method comprising: contacting the sample with an oligonucleotide primer pair specific for a fungal nucleic acid sequence that comprises the coding sequence for the 5.8S rRNA gene; amplifying a first amplified nucleic acid by a DNA polymerase chain reaction, wherein both primers of the oligonucleotide primer pair define the limits of the first amplified nucleic acid and wherein the first amplified nucleic acid comprises fungal nucleic acid sequence that comprises the coding sequence for the 5.8S rRNA gene; contacting the first amplified nucleic acid from step with a second 30 oligonucleotide primer pair, wherein the second oligonucleotide primer pair is specific for the H. capsulatum 5.8S rRNA gene, and wherein each second oligonucleotide primer is specific for a nucleotide sequence of the first amplified nucleic acid; [R:\LIBVV]03273.doc:sxc amplifying a second amplified nucleic acid by a DNA polymerase chain reaction, wherein the second oligonucleotide pair defines the limits of the second amplified nucleic acid; and detecting an amplification product of step whereby detecting the amplification product of step indicates the presence of H. capsulatum.

According to a fifth aspect of the present invention there is provided a method of detecting H. capsulatum in a sample, comprising: contacting the sample with a first oligonucleotide primer comprising the sequence of SEQ ID NO:1 and a second oligonucleotide primer comprising the sequence of SEQ ID NO:2; amplifying a first amplified nucleic acid by a DNA polymerase chain reaction, wherein the first and second oligonucleotide primers define the limits of the first amplified nucleic acid; contacting the first amplified nucleic acid from step with a third oligonucleotide primer comprising the sequence of SEQ ID NO:3 and a fourth oligonucleotide comprising the sequence of SEQ ID NO:4; amplifying a second amplified nucleic acid by a DNA polymerase chain reaction, wherein the third and fourth oligonucleotide primers define the limits of the second amplified nucleic acid; and 20 detecting an amplification product of step whereby detecting the amplification product of step indicates the presence of H. capsulatum.

SThe invention discloses an oligonucleotide primer pair including sequences specific for the 5.8S rRNA gene of Histoplasma capsulatum, to be used in the second stage of the PCR assay, or an oligonucleotide primer pair, each of which includes a sequence complementary to one or the other of the primer pair specific for the H. capsulatum 5.8S rRNA gene. In an embodiment, the oligonucleotide primer pair is disclosed as an oligonucleotide containing the sequence given by SEQ ID NO:3, and an oligonucleotide containing the sequence given by SEQ ID NO:4. The invention additionally discloses an Soligonucleotide containing a sequence complementary to that given in SEQ ID NO:3, and 30 an oligonucleotide containing a sequence complementary to that given in SEQ ID NO:4.

These complementary oligonucleotides are useful to prepare the actual PCR primers of the invention by the action of a DNA polymerase, and in probing test samples for the presence ofH. capsulatum DNA.

[R:\LIBVV]03273.doc:sxc The methods of the invention detect the presence of Histoplasma capsulatum in a sample. One method disclosed includes the steps of: providing a sample suspected of harboring H. capsulatum; preparing a first amplified nucleic acid by contacting the sample with a first solution comprising an oligonucleotide primer pair specific for a fungal nucleic acid sequence that comprises the coding sequence for the 5.8S rRNA gene, a first DNA polymerase, and a first mixture of deoxynucleotide triphosphates, in a first buffer, and carrying out a polymerase chain reaction on the first solution resulting therefrom; preparing a second amplified nucleic acid by contacting all or a portion of the first amplified nucleic acid from step with a second solution comprising an oligonucleotide primer pair specific for the H. capsulatum 5.8S rRNA gene, a second DNA polymerase, and a second mixture of deoxynucleotide triphosphates, in a second buffer, and carrying out a polymerase chain reaction on the second solution resulting therefrom; and detecting the presence of DNA derived from H. capsulatum in the second amplified nucleic acid, *e [R:\LIBVV]03273.doc:sxc whereby the presence of DNA derived from H. capsulatum in the second amplified nucleic acid indicates that H. capsulatum occurs in the sample. In a preferred embodiment of the above method, the oligonucleotide primer pair employed in step is specific for the fungal internal transcribed spacer (ITS) regions flanking the coding sequence for the 5.8S rRNA gene (see Figure 1).

The invention additionally discloses a method of detecting the presence of Histoplasma capsulatum in a sample, including providing a sample suspected of harboring H. capsulatum; preparing a first amplified nucleic acid by contacting the sample with a first solution comprising an oligonucleotide comprising the sequence given by SEQ ID NO:1, an oligonucleotide comprising the sequence given by SEQ ID NO:2, a first DNA polymerase, and a first mixture of deoxynucleoside triphosphates, in a first buffer, and carrying out a polymerase chain reaction on the first solution resulting therefrom; preparing a second amplified nucleic acid by contacting all or a portion of the first amplified nucleic acid from step with a second solution comprising an oligonucleotide comprising the sequence given by SEQ ID NO:3, an oligonucleotide comprising the sequence given by SEQ ID NO:4, a second DNA polymerase, and a second mixture of deoxynucleoside triphosphates, in a second buffer, and carrying out a polymerase chain reaction on the second solution resulting therefrom; and detecting the presence of DNA derived from H. capsulatum in the second amplified nucleic acid, whereby the presence of DNA derived from H. capsulatum in the second amplified 25 nucleic acid indicates that H. capsulatum occurs in the sample.

In preferred embodiments of the methods of the invention the samples can be environmental samples, including soil samples, or clinical samples from human subjects. Furthermore, in a preferred embodiment of the methods of the invention, the partial purification step includes separating any soil contained in the 30 sample from the H. capsulatum nucleic acid. In still another preferred embodiment ~of the invention, the first buffer contains bovine serum albumin. In additional preferred embodiments of the methods the detecting step includes gel electrophoresis of the second amplified nucleic acid and detecting any H.

WO 99/54508 PCT/US99/08731 capsulatum-specific DNA in the resulting gel, or contacting the second amplified nucleic acid with a labeled probe specific to H. capsulatum-specific DNA and detecting the label.

BRIEF DESCRIPTION OF THE DRAWING Figure 1. Schematic diagram of fungal ribosomal RNA genes.

Figure 2. Sensitivity and specificity of two-stage PCR for H. capsulatum DNA. Panel A: Gel electrophoretogram showing results of first PCR stage based on fungal-specific primers. Lane 1, 50 fg H. capsulatum DNA; Lane 2, 100 fg H.

capsulatum DNA; Lane 3, 1,000 fg H. capsulatum DNA; Lane 4, 25 ng Blastomyces dermatitidis DNA; Lane 5, 50 ng B. dermatitidis DNA; Lane 6, 100 ng B.

dermatitidis DNA. Panel B: Gel electrophoretogram showing results of second PCR stage based on H. capsulatum-specific primers. Lane 7, 50 fg H. capsulatum DNA; Lane 8, 100 fg H. capsulatum DNA; Lane 9, 1,000 fg H. capsulatum DNA; Lane 10, 25 ng B. dermatitidis DNA; Lane 11, 50 ng B. dermatitidis DNA; Lane 12, 100 ng B. dermatitidis DNA.

Figure 3. Effect of including bovine serum albumin as a buffer component, and gel filtration as a step, on inhibition of PCR amplification by soil. Lane 1, ng H. capsulatum DNA; Lane 2, 10 ng H. capsulatum DNA, untreated soil, and bovine serum albumin (BSA); Lane 3, 10 ng H. capsulatum DNA, BSA, and soil that had been treated with a Sephadex G-50 spin column; Lane 4, 10 ng H.

capsulatum DNA and soil that had been treated with a Sephadex G-50 spin column; Lane 5, 10 ng H. capsulatum DNA, BSA, and treatment with a Sephadex G-50 spin column; Lane 6, 10 ng H. capsulatum DNA, and treatment with a Sephadex G-50 spin column.

Figure 4. Detection of H. capsulatum DNA in soil samples using two-stage PCR. Panel A: Detection of H. capsulatum by PCR in soil spiked with H.

capsulatum spores. Lane 1, 10 pg H. capsulatum DNA; Lane 2, 10 H. capsulatum spores; Lane 3, Soil that is free of H. capsulatum spiked with 1,000 H. capsulatum spores; Lane 4, Soil that is free of H. capsulatum spiked with 500 H. capsulatum spores; Lane 5, Soil that is free of H. capsulatum; Lane 6, 100 bp ladder of DNA markers. Panel B: Detection of H. capsulatum by PCR in soil known to contain H.

-9- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 capsulatum. Lane 1, 1 pg H. capsulatum DNA; Lane 2, contaminated soil, sample "HC-13"; Lane 3, contaminated soil, sample "HC-14"; Lane 4, contaminated soil, sample "HC-14"; Lane 5, 10 H. capsulatum spores; Lane 6, negative control.

DETAILED DESCRIPTION OF THE INVENTION As used herein the terms "specific to" or "specific for" a target sequence, in relation to a nucleic acid sequence such as an oligonucleotide sequence, relate to a nucleotide sequence that hybridizes, under conditions used in given experimental circumstances, to the target but does not hybridize under those circumstances to sequences that are not target sequences. Nucleotide sequences that are specific for a particular target, such as the H. capsulatum target sequences that are included in the subject matter of the present invention, are those that include bases every one of which is complementary to the corresponding base on the target. The target nucleic acid sequences envisioned in this invention include those taht occur in all subspecies and strains of H. capsulatum currently known, and in equivalent subspecies and strains of H. capsulatum that may remain to be discovered. The nucleic acids and oligonucleotides of the invention, therefore, include all those molecules fully complementary to target sequences occurring in any subspecies or strain of H. capsulatum.

As used herein, in addition, "specificity" of a nucleic acid sequence for a target sequence also encompasses nucleic acids and oligonucleotides a small number of whose nucleotides may not be complementary to the corresponding nucleotide of the target sequence. Such sequences are still "specific" for the target sequence, as used herein, as long as the extent of deviation from complementarity remains functionally of no consequence. In particular, such a sequence is "specific" for the target sequence as long as it hybridizes effectively to the target sequence but does not hybridize to any sequence that is not a target sequence, under the conditions used in given experimental circumstances.

As used herein the term "polymerase chain reaction (PCR)" relates to a procedure whereby a limited segment of a nucleic acid molecule, which frequently is a desired or targeted segment, is amplified repetitively to produce a large amount of DNA molecules which consist only of the segment. The procedure SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 depends on repetition of a large number of replication cycles. In each cycle, two oligonucleotide primers bind to the segment, and define the limits of the segment.

A primer-dependent DNA polymerase then transcribes, or replicates, the strands to which the primers have bound. Thus in each cycle, the number of DNA duplexes is doubled.

As used herein the term "primer" or "oligonucleotide primer" relates to an oligonucleotide having a specific or desired nucleotide sequence which is complementary to a particular sequence on one of the strands of a DNA duplex.

When the primer is caused to hybridize to the specific sequence in a DNA duplex to which it is complementary, it may serve as the priming position, or the initiation position, for the action of a primer-dependent DNA polymerase activity.

The primer, once hybridized, acts to define one end of the operation of the replication activity of the polymerase on the duplex. A specific pair of primers is employed, wherein each hybridizes to one of the strands such that transcription, which proceeds from 5' to is in the direction leading to the site of hybridization of the second primer to the opposite strand of the duplex. After several rounds of hybridization and transcription, the amplified DNA produced is a segment having a defined length whose ends are defined by the sites to which the primers hybridize.

PCR is well known to skilled artisans in the fields of molecular biology and genetic engineering, and is described in general terms and with operational detail in, for example, "Current Protocols in Molecular Biology", Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly); "Molecular Cloning: A Laboratory Manual", 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989; "PCR Protocols: A Guide to Methods and Applications", Innis et al., Academic Press, NY 1990; and U.S.

Patent No. 4,965,188, issued Oct. 23, 1990 to Mullis et al.; all of which are incorporated herein by reference in their entirety.

The oligonucleotide primers of the invention are intended for use in a PCR-based amplification of a target segment of DNA from H. capsulatum. PCR relies on the action of a DNA polymerase such as Taq polymerase, to replicate the DNA segment beyond the 3' termini of the primers. Each primer may consist only of the nucleotides given by SEQ ID NOs:1-4, respectively. Alternatively, any primer may also contain additional sequences. If so, the hybridizing sequences in -11- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 the primer pair that specifically hybridize to the target nucleic acid, such as those given by SEQ ID NOs:1-4, must not be interrupted by any additional nucleotides.

Since polymerase extend a chain in the direction from 5' to the specific hybridizing sequences, such as the sequences given by SEQ ID NOs:1-4, must appear at the 3' end of any primer containing additional nucleotides.

Additionally oligonucleotides that include the complements of the primer sequence that hybridize to the target nucleic acid, such as the complements to the sequences given by SEQ ID NOs:1-4, are also disclosed in the invention. These may consist only of the respective complementary sequences, or they may contain additional sequences with the proviso that the respective complementary sequences are intact and not interrupted by any inserted nucleotides. Such complementary oligonucleotides may be employed as probes for H. capsulatum DNA. They may also be used to prepare the PCR primers of the invention by means of a DNA polymerase. For such purposes the complementary sequence must appear at the 5' end of the molecule such that action of the polymerase will generate a primer oligonucleotide having its complementary sequence at its 3' end, as required according to the discussion in the preceding paragraph.

A wide variety of samples suspected of harboring H. capsulatum may be analyzed by the methods of the present invention. For example, in order to protect the public health, the invention envisions assaying environmental samples containing soil for the presence of the pathogen. As used herein, the term "soil" is intended broadly to include any portion of earth, soil, dust, or naturally occurring powders, as well as soils that include decaying vegetation, soils that include decaying feces from birds and bats, and the like. Since it is known that spores of H. capsulatum occur with relatively high prevalence in decaying deposits of feces from birds or bats, it is to be understood that significant locations from which samples may be drawn include places where these deposits are prevalent, such as chicken or poultry coops, sheds, and yards; barns; caves; and the like.

Additionally, clinical samples drawn from human subjects may be analyzed by the methods of the present invention. Candidate subjects from whom samples may be obtained are those suspected of having contracted fresh histoplasmosis as a result of symptomology. Persons exhibiting symptoms such as mild malaise and flu-like illness may be suspected of suffering from newly contracted -12- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 histoplasmosis. In addition, an important group of candidate subjects includes those who may be immune compromised, such as the very young, the very old, those receiving immunosuppressive pharmacotherapy, those suffering from cancer, and those suffering from immune suppressing diseases such as acquired immune deficiency disease. Such individuals are susceptible to a recrudescence of histoplasmosis from a latent infection. Latency may have originated from earlier endocytosis of H. capsulatum by pulmonary macrophages, or from the calcified deposits within the lungs, produced when growth of the yeast form is inhibited by host immune responses. In such individuals, chronic or disseminated forms of the disease could occur. Chronic pulmonary histoplasmosis leads to symptoms that are similar to those of tuberculosis, and last for many months. Disseminated infections produce symptoms usually involving chronic fever, weight loss, and so forth. In addition, ocular histoplasmosis may lead to visual loss including blindness. Symptoms such as those described here would lead to a suspicion of recurring histoplasmosis in these patients. As described above, either macrophages or calcified deposits, or other sources within the body may serve as a reservoir of latent infection for extended periods of time.

Samples from candidate subjects may be drawn from several sources, including by way of nonlimiting example, blood or any other body fluids, and importantly in the methods of the invention, those fluids in which macrophages that could harbor H. capsulatum are found, biopsies from any tissues of the body, including lung calcifications or other locations where H. capsulatum infection is suspected, and the like.

In order to practice the method of the invention, a sample suspected of harboring H. capsulatum is obtained. A sample originating from an environmental soil sample is generally understood to include H. capsulatum spores. The sample is concentrated and subjected to a procedure that may partially purify H. capsulatum nucleic acids compared to the state of the sample as provided. The spores are then inactivated by heat treatment, such as exposure to temperatures in the range of about 60°C to about 70°C, preferably about 65°C, for times ranging from about so min to about 2 hrs., preferably about 60 min. The samples are then subjected to a process that separates the samples from much of the remaining matter in the soil sample, including inorganic mineral particles and organic matter -13- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 that may be present. Such partial purification, for example, may be achieved by placing the sample on top of a gel permeation medium such as, for example, Sephadex T M (Pharmacia Biotech, Piscataway, NJ) and centrifuged, whereupon the spores and/or the fungal DNA collect in the permeate (Tsai, and Olson, Appl. Envir. Microbiol. 58, 2292-2295 (1992)). Since soil may be inhibitory to the PCR process, it is generally preferred that such a partial purification be carried out on such samples..

Clinical samples may include H. capsulatum either in the spore or yeast form. Clinical samples may be concentrated and partially purified by procedures similar to those applied with soil samples.

Fungal DNA is released from fungal cells thus becoming available for the PCR amplification reaction. Without wishing to be limited by theory, it is believed that the-preliminary heat treatment described above, as well as the heating that occurs in the first step of the PCR process, described further below (see Example disrupts the H. capsulatum cells and liberates the nucleic acids.

Of course, other methods of liberating the nucleic acids may be used if desired.

The sample suspected of harboring H. capsulatum nucleic acids is then subjected to a two-stage nested PCR amplification. Nested PCR significantly enhances both the specificity and the sensitivity of the assay, since more than one pair of primers is used in sequential PCR reactions. The DNA segment selected by the second primer pair must reside within the segment produced by the first primer pair. In the first PCR stage, a portion or all of the sample is contacted with a first pair of primers and a first DNA polymerase. These primers are an oligonucleotide primer pair specific for a fungal nucleic acid sequence that includes the coding sequence for the 5.8S rRNA gene. In a preferred embodiment of the invention, the oligonucleotides of the first primer pair are specific for the internal transcribed spacer (ITS) regions flanking the gene for 5.8S ribosomal RNA in a broad range of fungal species, shown in Figure 1. In a particular embodiment of the invention provided in the Examples, an ITS oligonucleotide containing the sequence given by SEQ ID NO:1 (ITS-1 in Figure and an ITS oligonucleotide containing the sequence given by SEQ ID NO:2 (ITS-4 in Figure are employed (White, PCR Protocols: A guide to Methods and Applications, Academic Press, 1990, pp. 315-322). This primer pair is specific for most fungi, and yields PCR -14- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 products of approximately 600 to 650 bp (Taylor, J. Clin. Microbiol. 32, 253- 255 (1994)). Important genera of fungus detected include Cryptococcus, Candida strains as well as Histoplasma and Blastomyces.

As noted above, the test sample may contain further substances that have an inhibitory effect on the PCR process. Samples originating from soil, for example, may contain soluble components, such as humic acid, that interfere with the method. Accordingly, appropriate components must be introduced that neutralize any potential inhibitors or interfering substances. One additive found to be effective in the method of the present invention is bovine serum albumin (BSA) (Kreader, Appl. Envir. Microbiol. 62, 1102-1106 (1996)); this protein is included as a component of the buffer for the first stage of PCR in a significant embodiment of the invention.

PCR amplification is then conducted on the resulting mixture using a temperature program and for a number of thermal cycles sufficient to amplify the target DNA, if present. An example of a temperature program is an initial heating step at a high temperature (about 85 to about 990C) for a short time, followed by cycles of melting at a similar high temperature (about 85 to about 99 0 hybridization of the PCR probes at a low temperature (about 40 to about 0 and synthesis of new DNA strands at a moderate temperature (about 65 to about 80 0 The number of thermal cycles may generally range from about to about 40 or more. Advantageously a larger number of cycles is used rather than a smaller number. The PCR reaction is conveniently carried out in any PCR thermal cycling apparatus available commercially, such as those manufactured by Perkin Elmer Applied Biosystems, Foster City, CA, or Qiagen, Chatsworth, CA.

The amplified DNA that results from the first PCR stage is a segment of DNA from H. capsulatum and related fungi. Omission of this first PCR stage was found to diminish the sensitivity and specificity of the method.

In the second PCR stage, a portion or all of the sample is contacted with a second pair of primers and a second DNA polymerase. The second pair of primers contains sequences found within the DNA fragment that is the product of the first stage of amplification, and that are specific for the sequence coding for the H. capsulatum 5.8S rRNA gene (see Figure In a preferred embodiment of the invention, an oligonucleotide containing the sequence given by SEQ ID NO:3 SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 (HC-1 in Figure and an oligonucleotide containing the sequence given by SEQ ID NO:4 (HC-2 in Figure PCR amplification is then conducted on the resulting mixture a second time, using similar procedures as with the first stage.

The buffer used in the second stage may or may not contain BSA. This stage amplifies the nested, or inner, segment only of H. capsulatum-specific DNA contained in the amplified larger DNA segment from the first amplification stage.

The first and second DNA polymerase used in the present invention are those DNA polymerase commonly employed in PCR amplification, especially DNA polymerase derived from thermophilic bacteria. The first and second DNA polymerase may be the same or different. Generally, it is preferred that the first and second DNA polymerase be the same. As those skilled in the art will realize, the first DNA polymerase may be carried over from the first PCR reaction into the second, nested PCR reaction, and may provide some or all of the second DNA polymerase in the second stage. Generally, however, it is preferred that additional DNA polymerase be added to the second stage.

The amplified DNA resulting from the second amplification is then subjected to a procedure which detects the presence of the DNA segment originating specifically from H. capsulatum. Several detection methods are available for this purpose. These include, by way of nonlimiting example, gel electrophoresis of the amplification product, and hybridization assays using a probe oligonucleotide, especially a probe oligonucleotide which is labeled. Gel electrophoresis resolves nucleic acids according to their size, and may be conducted, for example, in agarose gels. After electrophoresis nucleic acids are detected using a means which produces a visual image of the resolved nucleic acids in the gel, such as radioactive labeling of the DNA and exposure to film, or staining with a fluorescent dye such as ethidium bromide. It is expected to visualize a band of DNA having the size expected for the second fragment produced in the nested PCR.

Alternatively, an oligonucleotide probe may be applied to the product of the second PCR amplification to hybridize with a portion of the second fragment of H. capsulatum DNA. In general, such probes are labeled. Examples of probe oligonucleotides include those containing the sequences given by SEQ ID NOs:l- -16- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 4, and oligonucleotides containing sequences that are complementary to those given by SEQ ID NOs:1-4.

Hybridization assays are discussed by Hall (1993). The label incorporated into the probe may be, by way of nonlimiting example, radioactive labels, biotin, enzymes, digoxigenin, fluorescent probes, and chemiluminescent probes.

Radioactive labels include radioactive isotopes incorporated into the structure of the probe oligonucleotide. Biotin may be incorporated into the probe by use of biotinylated nucleotides, and digoxigenin by incorporating digoxigenin-substituted nucleotides. Biotin reacts specifically with streptavidin or avidin, which itself may be conjugated to an enzyme, the enzyme acting on a substrate to produce a detectable product. Digoxigenin may bind with a digoxigenin-specific antibody which likewise may be conjugated to an enzyme. Enzyme labels may also be conjugated directly to the probe. A common way of generating chemiluminescence is via an appropriate enzyme which acts on a substrate to produce light as one product of the reaction.

When a detection method produces a result indicating that the DNA segment from the second stage of the nested PCR is present, it is concluded that the original sample contained H. capsulatum. Conversely, if no evidence of the DNA segment is detected after the second stage of the nested PCR, it is concluded that, within the level of detection available from the method, the sample was free of H. capsulatum. The present method is highly sensitive. It is estimated that this method can detect DNA from as few as 5-10 H. capsulatum spores or cells in a typical sample (less than about 1 mg to about 2 Furthermore, it is specific for H. capsulatum among related fungal species. Additionally, since the present method requires only about two days, it is accomplished far faster than the mouse inoculum assay, which normally requires about 6-8 weeks.

EXAMPLES

Materials Soil samples were shown to contain H. capsulatum spores using the mouse inoculum assay. Clinical samples may contain H. capsulatum spores, or they may contain cells of the yeast form; the mouse inoculum assay may be used to establish -17- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 the presence of H. capsulatum in clinical samples as well. H. capsulatum DNA was isolated from H. capsulatum strain G-217B. Blastomyces dermatitidis DNA was a generous gift from Dr. Elizabeth Keath, St. Louis Univ.

Methods.

The soil samples, and the spores, were inactivated by exposure to a temperature of 65 0 C for 1 hr. The samples were then suspended in isotonic saline containing 0.01% Tween 80

T

For soil, approximately 100 mg was added to about 900 pL of the saline. The sample was mixed by vigorous vortexing and allowed to settle for 30 minutes. 50 gL aliquots of the upper portion of the soil suspension were partially purified by use of Sephadex T M G-50 spin columns (4 cm x 0.7 cm) containing approximately 1 ml of packed gel. Upon centrifugation the spores were found in the eluate, whereas any bulk soil remained on the surface of the column; low molecular weight contaminants were retained within the gel.

This initial treatment yields partially purified preparations.

Nested PCR was carried out using methods generally described in, for example, "Current Protocols in Molecular Biology", Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly), and "Molecular Cloning: A Laboratory Manual", 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989. Samples were derived from purified DNA, fungal spores, or the partially purified soil extracts prepared as described in the preceding paragraph. Purified DNA, fungal spores, or partially purified soil extracts were added to a 50 pL reaction volume containing 10 mM Tris (pH 50 mM KC1, 2.5 mM MgCl,, 0.1% Triton X-100 T M 5% glycerol, 8 mg/mL bovine serum albumin (BSA), 0.2 mM deoxyribonucleoside triphosphates (dNTPs), 2 units of Taq DNA polymerase, and 1 pM each of the primers ITS-1 and ITS-4 (see Figure which are considered to be generic for a broad range of fungi, and whose sequences are given respectively by: 5'-TCCGTAGGTGAACCTGCGG-3' (SEQ ID NO:1) and -18- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 5'-TCCTCCGCTTATTGATATGC-3' (SEQ ID NO:2).

PCR was carried out using a thermal program of heating to 95 0 C for 3 min., followed by 40 cycles of incubating at 95 0 C for 1 min., 55 0 C for 1 min., and 72 0 C for 1 min.

The second round of PCR was started on a dilution of the product of the first round by between 1:200 and 1:1000. 1 pM each of the primers HC-1 and HC-2 (see Figure 1) which were devised to be specific for H. capsulatum, and whose sequences are given respectively by: 5'-GGAGCCTCTGACCGGGAC-3' (SEQ ID NO:3) and 5'-GCACGTCCCACCGGTCAG-3' (SEQ ID NO:4), were employed. The reaction mixture (50 pL) also contained 10 mM Tris (pH 50 mM KC1, 2.5 mM MgCl,, 0.2 mM dNTP's, and 2 units of Taq DNA polymerase. The reaction was carried out using a thermal cycle of heating to 95 0 C for 3 min., followed by 40 cycles of incubating at 95 0 C for 1 min., 60 0 C for 1 min., and 72°C for 1 min.

The amplified product of the second round was subjected to agarose gel electrophoresis using a gel concentration of Bands were detected upon staining with SyBr Green Dye (Molecular Probes, Eugene, OR).

Example 1. Detection of H. capsulatum DNA. This example illustrates the sensitivity and specificity of the method of the invention. Samples of purified DNA from the target organism, H. capsulatum, and from a related fungus, Blastomyces dermatitidis, were analyzed using the two-stage, or nested, PCR method of the invention. Results are shown in Figure 2. Panel A depicts the results obtained after the first, or fungus-specific, round of PCR using the primers given by SEQ ID NO:1 and SEQ ID NO:2). A fragment having the expected size of 600 bp is observed in samples of H. capsulatum DNA at levels of -19- SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 100 femtogram (fg; 1 fg 10-" g) and 1,000 fg (1 pg), but not at 50 fg (Lanes 2, 3, and 1, respectively). Samples of DNA from the related fungus, B. dermatitidis, (employed at concentrations of 25, 50, and 100 ng) yielded a DNA fragment of the same size (Lanes 4, 5, and 6, respectively).

The second round of PCR, using the H. capsulatum-specific primers (SEQ ID NO:3 and SEQ ID NO:4) gives results shown in Panel B of Figure 1. A DNA fragment of the expected size, 400 bp, is observed for samples of H. capsulatum DNA that originally contained 100 fg and 1,000 fg (Lanes 8 and 9, respectively) but not for the sample originally containing 50 fg of DNA (Lane The samples containing B. dermatitidis DNA, show no detectable DNA in this second round (Lanes 10-12) at loadings in the original samples of up to 100 ng, or one million times that of the lowest amount of H. capsulatum DNA that was detectable.

These results show that the nested PCR method using the primers of SEQ ID NOs: 1-4 is highly sensitive to small amounts of H. capsulatum DNA in a sample, while being specific for this species and not detecting the DNA of a related fungal species, even when present in vast excess. In assays in which only the second primer pair was used in a single-stage PCR amplification, the specificity and sensitivity of the assay were inadequate (not shown). These observations demonstrate that the two-stage PCR assay of the invention provides high sensitivity and specificity for the detection of H. capsulatum in a sample.

Example 2. Inhibition of PCR Amplification by Soil. This example demonstrates that the presence of soil in the PCR assay medium inhibits PCR amplification. Figure 3 shows the results of the first (fungus-specific) round of PCR for samples containing 10 ng DNA. In comparison with Lane 1, which shows an experiment with H. capsulatum DNA only, Lane 2 shows that a sample containing H. capsulatum DNA, uncontaminated soil, and 400 ng BSA in the amplification medium, and which was not subjected to purification by centrifugation through Sephadex G-50

T

is inhibited from amplifying the DNA.

Likewise, a sample containing soil and which was subjected to purification, but which lacked BSA in the PCR buffer, also is inhibited from amplifying DNA (Lane Both purification and the presence of BSA in the PCR buffer are required to prevent inhibition of PCR amplification by the soil (Lane Lanes 5 (BSA and SUBSTITUTE SHEET (RULE 26) WO 99/54508 PCT/US99/08731 purification) and 6 (purification only) provide positive controls for samples omitting soil from the assay. In separate experiments (not shown) the inhibitory effects of humic acid were also found to be overcome using similar techniques.

Example 3. Two-Stage PCR on Soil Samples. Figure 4 presents results of nested PCR on soil that is free of H. capsulatum but spiked with H. capsulatum spores, and on soil samples shown to be contaminated using the indirect mouse assay (Ajello, L. and Weeks, in Occupational Mycoses, A Text, edited by A.F.

DiSalvo, Leas Febiger, Philadelphia, pp.229 238, 1983; Ajello, L. and Runyon, J. Bacteriol. 66:34-40, 1953). The uncontaminated soil was obtained from a cultivated plant bed. The contaminated soil originated from a vacant church in Manchester, TN that had been subjected to evaluation for the presence of H.

capsulatum in 1992 by the Division of Surveillance, Hazard Evaluations, and Field Studies, National Institute of Occupational Safety and Health. 100 mg of soil was employed in each assay. 1/100th of the sample solution was taken at the point of sampling to initiate PCR.

Figure 4, Panel A shows that in the absence of soil, 10 pg of H. capsulatum DNA (Lane 1) and 10 H. capsulatum spores (Lane 2) yield the expected 400 bp band. A sample containing noncontaminated soil alone remains blank (Lane Samples of soil, with 500 (Lane 4) or 1000 (Lane 3) H. capsulatum spores added also give positive detection of DNA. Lane 6 contains a DNA ladder of bands spaced 100 bp apart. Panel B shows samples from two batches of contaminated soil (Lanes 2-4, samples HC-13, HC-14 and HC-14, respectively). HC-13 and HC- 14 were taken from different regions of the environmentally contaminated site.

They yielded bands of DNA at 400 bp, as do positive controls of 1 pg H.

capsulatum DNA (Lane 1) and 10 H. capsulatum spores in the absence of soil (Lane A negative control is shown in Lane 6.

These experiments show that the present method using the nested primer pairs of SEQ ID NOs: 1-4 permit sensitive detection of H. capsulatum spores in environmental soil samples.

-21- SUBSTITUTE SHEET (RULE 26) EDITORIAL NOTE APPLICATION NUMBER 36588/99 The following Sequence Listing pages 1 to 2 are part of the description. The claims pages follow on pages "22" to "24".

WO 99/54508 PCT/US99/08731 1 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: SCHAFER, MILLIE P REID, THOMAS M (ii) TITLE OF INVENTION: RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM (iii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: FITCH, EVEN, TABIN FLANNERY STREET: 135 SOUTH LASALLE STREET, SUITE 900 CITY: CHICAGO STATE: IL COUNTRY: USA ZIP: 60603-4277 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE:

CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION: NAME: KABA, RICHARD A REGISTRATION NUMBER: 30,562 (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: (312) 372-7842 TELEFAX: (312) 372-7848 INFORMATION FOR SEQ ID NO:l: SEQUENCE CHARACTERISTICS: LENGTH: 19 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: ORGANISM: HISTOPLASMA CAPSULATUM (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: TCCGTAGGTG AACCTGCGG 19 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear SUBSTITUTE SHEET (RULE 26) WO 99/54508 2 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: ORGANISM: HISTOPLASMA CAPSULATUM (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TCCTCCGCTT ATTGATATGC INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: ORGANISM: HISTOPLASMA CAPSULATUM (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GGAGCCTCTG ACCGGGAC 18 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: ORGANISM: HISTOPLASMA CAPSULATUM (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GCACGTCCCA CCGGTCAG 18 PCT/US99/08731 SUBSTITUTE SHEET (RULE 26)

Claims (18)

1. An oligonucleotide primer pair comprising sequences specific for the 5.8S rRNA gene of Histoplasma capsulatum, wherein both primers of said primer pair are specific for Histoplasma capsulatum 5.8S rRNA, and wherein both primers of said pair specifically amplify 5.8S rRNA gene sequence, or an oligonucleotide comprising a sequence complementary to one or the other of the primer pair specific for the H. capsulatum 5.8S rRNA gene.

2. An oligonucleotide comprising a sequence given by SEQ ID NO:3 or a sequence complementary to that given by SEQ ID NO:3, wherein the sequence of SEQ ID NO:3 defines the 3' end of the oligonucleotide or wherein the sequence complementary to SEQ ID NO:3 defines the 3' end of the oligonucleotide.

3. An oligonucleotide comprising a sequence given by SEQ ID NO:4 or a sequence complementary to that given by SEQ ID NO:4, wherein the sequence of SEQ ID NO:4 defines the 3' end of the oligonucleotide or wherein the sequence complementary to SEQ ID NO:4 defines the 3' end of the oligonucleotide.

4. A method of detecting H. capsulatum.in a sample, said method comprising: contacting the sample with an oligonucleotide primer pair specific for a fungal nucleic acid sequence that comprises the coding sequence for the 5.8S rRNA gene; amplifying a first amplified nucleic acid by a DNA polymerase chain 20 reaction, wherein both primers of the oligonucleotide primer pair define the limits of the first amplified nucleic acid and wherein the first amplified nucleic acid comprises fungal nucleic acid sequence that comprises the coding sequence for the 5.8S rRNA gene; contacting the first amplified nucleic acid from step with a second oligonucleotide primer pair, wherein the second oligonucleotide primer pair is specific for the H. capsulatum 5.8s rRNA gene, and wherein each second oligonucleotide primer is specific for a nucleotide sequence of the first amplified nucleic acid; amplifying a second amplified nucleic acid by a DNA polymerase chain reaction, wherein the second oligonucleotide pair defines the limits of the second amplified nucleic acid; and S 30 detecting an amplification product of step whereby detecting the amplification product of step indicates the presence of H. capsulatum.

5. The method of claim 4 wherein the sample is an environmental sample comprising soil or a clinical sample from a human subject. [R:\LIBVV]03273.doc:sxc

6. The method of claim 4 wherein before step the sample is subjected to partial purification comprising separation of any soil or contaminants contained in the sample from the H. capsulatum nucleic acid.

7. The method of claim 4 wherein the first amplified nucleic acid is amplified in a solution comprising bovine serum albumin.

8. The method of claim 4 wherein the detecting step comprises performing gel electrophoresis of the second amplified nucleic acid and detecting any H. capsulatum- specific DNA.

9. The method of claim 4 wherein the detecting step comprises contacting the o0 second amplified nucleic acid with a labeled probe specific to H. capsulatum DNA and detecting the label.

The method of claim 4 wherein the oligonucleotide primer pair employed in step is specific for the fungal internal transcribed spacer regions flanking the coding sequence for the 5.8S rRNA gene.

11. A method of detecting H. capsulatum in a sample, comprising: contacting the sample with a first oligonucleotide primer comprising the sequence of SEQ ID NO:1 and a second oligonucleotide primer comprising the sequence of SEQ ID NO:2; amplifying a first amplified nucleic acid by a DNA polymerase chain 20 reaction, wherein the first and second oligonucleotide primers define the limits of the first amplified nucleic acid; contacting the first amplified nucleic acid from step with a third oligonucleotide primer comprising the sequence of SEQ ID NO:3 and a fourth oligonucleotide comprising the sequence of SEQ ID NO:4; amplifying a second amplified nucleic acid by a DNA polymerase chain reaction, wherein the third and fourth oligonucleotide primers define the limits of the second amplified nucleic acid; and detecting an amplification product of step whereby detecting the amplification product of step indicates the presence of H. capsulatum.

12. The method of claim 11 wherein the sample is an environmental sample comprising soil or a clinical sample from a human subject.

13. The method of claim 11 wherein before step the sample is subjected to partial purification comprising separation of any soil or contaminants contained in the sample from the H. capsulatum nucleic acid. [R:\LIBVV]03273.doc:sxc

14. The method of claim 11 wherein the first amplified nucleic acid is amplified in a solution comprising bovine serum albumin.

The method of claim 11 wherein the detecting step comprises performing gel electrophoresis of the second amplified nucleic acid and detecting any H. capsulatum- specific DNA.

16. The method of claim 11 wherein the detecting step comprises contacting the second amplified nucleic acid with a labeled probe specific to H. capsulatum DNA and detecting the label.

17. An oligonucleotide primer pair comprising sequences specific for the 5.8S rRNA gene of Histoplasma capsulatum substantially as hereinbefore described with reference to any one of the examples.

18. A method of detecting Histoplasma capsulatum in a sample substantially as hereinbefore described with reference to any one of the examples. Dated 20 October, 2003 The Government of the United States of America represented by The Secretary of the Department of Health and Human Services Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON e ee [R:\LIBVV]03273.doc:sxc